Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed.

Published byἝκτωρ Αλεβιζόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed."— Presentation transcript:

1 Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed human PBMCs. (a, A–C) EBV-transformed human PBMCs incubated with UsC for 1 min; (a, D–F) EBV-trans... Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed human PBMCs. (a, A–C) EBV-transformed human PBMCs incubated with UsC for 1 min; (a, D–F) EBV-transformed human PBMCs incubated with UsC for 2 min; (a, G–I) EBV-transformed human PBMCs incubated with UsC for 4 min; (A, D, G) fluorescence; (B, E, H) transmitted light overlay; (C, F, I) merged image (fluorescence+transmitted light overlay); (b) lymphadenopathy in the lpr-water group (A–D), lpr-CU group (E–H) and lpr-TU group (I–L). Arrows point to enlarged lymph nodes; (c) enlarged image of UsC uptake by EBV-transformed human PBMCs. (Left panel) fluorescence; (middle panel) transmitted light overlay; (right panel) merged image (fluorescence+transmitted light overlay). CU, curcumin; TU, turmeric. Biji T Kurien et al. Lupus Sci Med 2015;2:e000114 ©2015 by Lupus Foundation of America

Download ppt "Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed."

Similar presentations

Supplementary Figure 1. [ 18 F]FHBG is not retained, phosphorylated, or incorporated into the DNA of B16 cells. (A-C) For the in vitro studies a panel.

Supplementary Figure 1. [ 18 F]FHBG is not retained, phosphorylated, or incorporated into the DNA of B16 cells. (A-C) For the in vitro studies a panel.
Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Synaptotagmin SYTA Forms ER-Plasma Membrane Junctions that Are Recruited to Plasmodesmata for Plant Virus Movement  Amit Levy, Judy Y. Zheng, Sondra G.

Synaptotagmin SYTA Forms ER-Plasma Membrane Junctions that Are Recruited to Plasmodesmata for Plant Virus Movement  Amit Levy, Judy Y. Zheng, Sondra G.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Flow cytometry analysis of TNF-β- and IL-10-producing CD33+ cells.

Flow cytometry analysis of TNF-β- and IL-10-producing CD33+ cells.
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
STARD3 favors cholesterol accumulation in endosomes

STARD3 favors cholesterol accumulation in endosomes
Axonal swelling and impairment of dendritic development in Purkinje cells from Pex14ΔC/ΔC BL/ICR mouse upon treatment with BDNF. Axonal swelling and impairment.

Axonal swelling and impairment of dendritic development in Purkinje cells from Pex14ΔC/ΔC BL/ICR mouse upon treatment with BDNF. Axonal swelling and impairment.
Figure 1 VGCC antibody uptake in cerebellar slice culture

Figure 1 VGCC antibody uptake in cerebellar slice culture
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.
Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.
Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.

Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.
Multiangle-TIRF imaging of EGF-activated clathrin-mediated endocytosis

Multiangle-TIRF imaging of EGF-activated clathrin-mediated endocytosis
Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.
The distribution of lamin C and emerin in lymphoblastoid cell lines.

The distribution of lamin C and emerin in lymphoblastoid cell lines.
Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.

Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.

Similar presentations

Ads by Google